OncoCyte Corporation (OCX)

OncoCyte Statistics

Total Valuation

OncoCyte has a market cap or net worth of $87.51 million. The enterprise value is $82.54 million.

Market Cap	87.51M
Enterprise Value	82.54M

Important Dates

The last earnings date was Monday, March 24, 2025, after market close.

Earnings Date	Mar 24, 2025
Ex-Dividend Date	n/a

Share Statistics

OncoCyte has 28.60 million shares outstanding. The number of shares has increased by 70.84% in one year.

Current Share Class	28.60M
Shares Outstanding	28.60M
Shares Change (YoY)	+70.84%
Shares Change (QoQ)	+26.75%
Owned by Insiders (%)	12.31%
Owned by Institutions (%)	7.63%
Float	10.90M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	21.26
Forward PS	102.12
PB Ratio	-7.13
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	43.88
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.62

Current Ratio	1.62
Quick Ratio	1.41
Debt / Equity	n/a
Debt / EBITDA	0.01
Debt / FCF	n/a
Interest Coverage	-276.75

Financial Efficiency

Return on equity (ROE) is -910.86% and return on invested capital (ROIC) is -146.37%.

Return on Equity (ROE)	-910.86%
Return on Assets (ROA)	-26.42%
Return on Invested Capital (ROIC)	-146.37%
Return on Capital Employed (ROCE)	-83.60%
Revenue Per Employee	$38,388
Profits Per Employee	-$1.24M
Employee Count	49
Asset Turnover	0.03
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +4.44% in the last 52 weeks. The beta is 0.79, so OncoCyte's price volatility has been lower than the market average.

Beta (5Y)	0.79
52-Week Price Change	+4.44%
50-Day Moving Average	2.80
200-Day Moving Average	2.84
Relative Strength Index (RSI)	45.49
Average Volume (20 Days)	106,921

Short Selling Information

The latest short interest is 373,800, so 1.31% of the outstanding shares have been sold short.

Short Interest	373,800
Short Previous Month	305,523
Short % of Shares Out	1.31%
Short % of Float	3.43%
Short Ratio (days to cover)	3.11

Income Statement

In the last 12 months, OncoCyte had revenue of $1.88 million and -$60.93 million in losses. Loss per share was -$4.66.

Revenue	1.88M
Gross Profit	828,000
Operating Income	-23.25M
Pretax Income	-36.35M
Net Income	-60.93M
EBITDA	-21.68M
EBIT	-23.25M
Loss Per Share	-$4.66

Balance Sheet

The company has $8.64 million in cash and $3.66 million in debt, giving a net cash position of $4.97 million or $0.17 per share.

Cash & Cash Equivalents	8.64M
Total Debt	3.66M
Net Cash	4.97M
Net Cash Per Share	$0.17
Equity (Book Value)	-12.27M
Book Value Per Share	-0.70
Working Capital	4.48M

Cash Flow

In the last 12 months, operating cash flow was -$20.71 million and capital expenditures -$516,000, giving a free cash flow of -$21.23 million.

Operating Cash Flow	-20.71M
Capital Expenditures	-516,000
Free Cash Flow	-21.23M
FCF Per Share	-$0.74

Margins

Gross Margin	44.02%
Operating Margin	-1,235.89%
Pretax Margin	-3,225.04%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

OncoCyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-70.84%
Shareholder Yield	-70.84%
Earnings Yield	-69.62%
FCF Yield	-24.26%

Analyst Forecast

The average price target for OncoCyte is $4.56, which is 49.02% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$4.56
Price Target Difference	49.02%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on July 25, 2023. It was a reverse split with a ratio of 0.05:1.

Last Split Date	Jul 25, 2023
Split Type	Reverse
Split Ratio	0.05:1

Scores

OncoCyte has an Altman Z-Score of -15.51 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-15.51
Piotroski F-Score	4